ArticleBMC immunology2009
Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells.
Article in BMC immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Ex vivo-expanded allogeneic Vδ2 T cells specifically reduce reservoirs of HIV-1 following latency reversal.JCI insight · 2026Article
- Review
- Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity.Nature immunology · 2021Article
- Article
- Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies.Stem cell research & therapy · 2020Review
- Review
- γδ T cells: an immunotherapeutic approach for HIV cure strategies.JCI insight · 2018Article
- Interleukin-18 activates Vγ9Vδ2Immunology · 2017Article
- Human γδT-cell subsets and their involvement in tumor immunity.Cellular & molecular immunology · 2017Review
- Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Article
- γδ T Cells in HIV Disease: Past, Present, and Future.Frontiers in immunology · 2014Review
- Reply to Hartjen et al.The Journal of infectious diseases · 2013Article
- Human cord blood γδ T cells expressing public Vγ2 chains dominate the response to bisphosphonate plus interleukin-15.Immunology · 2013Article
- Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes.Oncoimmunology · 2012Article
- Review
- Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.PloS one · 2012Article
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.British journal of cancer · 2011Article
- Impact of age, gender, and race on circulating γδ T cells.Human immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundIn lymphocyte subsets, expression of CD56 (neural cell adhesion molecule-1) correlates with cytotoxic effector activity. For cells bearing the Vgamma2Vdelta2 T cell receptor, isoprenoid pyrophosphate stimulation leads to uniform activation and proliferation, but only a fraction of cells express CD56 and display potent cytotoxic activity against tumor cells. Our goal was to show whether CD56 expression was regulated stochastically, similar to conventional activation antigens, or whether CD56 defined a lineage of cells committed to the cytotoxic phenotype.
resultsTracking individual cell clones defined by their Vgamma2 chain CDR3 region sequences, we found that CD56 was expressed on precursor cytotoxic T cells already present in the population irrespective of their capacity to proliferate after antigen stimulation. Public T cell receptor sequences found in the CD56+ subset from one individual might appear in the CD56- subset of another donor. The commitment of individual clones to CD56+ or CD56- lineages was stable for each donor over a 1 year interval.
conclusionThe ability to express CD56 was not predicted by TCR sequence or by the strength of signal received by the TCR. For gammadelta T cells, cytotoxic effector function is acquired when cytotoxic precursors within the population are stimulated to proliferate and express CD56. Expression of CD56 defines a committed lineage to the cytotoxic phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.